FDA Grants Priority Review for Dolutegravir in Newborns With HIV
The FDA granted Priority Review for ViiV Healthcare’s dolutegravir to treat newborns with HIV, setting an action date of August 25, 2026.
Read MoreALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
The FDA granted Priority Review for ViiV Healthcare’s dolutegravir to treat newborns with HIV, setting an action date of August 25, 2026.
Read More